Merz Therapeutics to present robust data on XEOMIN® (incobotulinumtoxinA) at Toxins 2022 Conference in New Orleans, LA

RALEIGH, N.C. – July 27, 2022 – Merz Therapeutics announced today the presentation of data from 10 accepted abstracts on XEOMIN^® (incobotulinumtoxinA) at TOXINS 2022: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins, taking place in New Orleans, LA July 27-30.

“Merz Therapeutics is excited to present strong data at the global TOXINS 2022 conference, and share important updates and clinical developments for XEOMIN, including data on clinical benefits to children and adolescents living with movement disorders in the United States,” said Prof. Dr. Florian Heinen, Head of Pediatric Neurology at LMU University Hospital Munich.* “The data assessing the ability of XEOMIN to help improve pain in children living with movement disorders is an important finding, and I am proud to be involved in this research.”

The following presentations will be shared at the TOXINS meeting and are intended to enhance the exchange of scientific information. All associated abstracts will be published in an online supplemental issue of Toxicon.

• Prevalence of spasticity-related pain in a clinical study population of children/adolescents with cerebral palsy, Florian Heinen, Michaela Bonfert, Petr Kaňovský, A. Sebastian Schroeder, Henry G. Chambers, Edward Dabrowski, Thorin L. Geister, Angelika Hanschmann, Michael Althaus, Marta Banach, Deborah Gaebler-Spira

• Injections of IncobotulinumtoxinA at Intervals Less Than 10 weeks Are Effective and Safe for Cervical Dystonia Patients With Inadequate Benefit From Standard Injection Intervals, Cynthia Comella, Robert Hauser, Stuart Isaacson, Georg Comes, Michael Hast, David Charles
• Treatment of Cervical Dystonia Using Shorter IncobotulinumtoxinA Injection Intervals Improves Patient-Reported Outcomes in Those With Inadequate Benefits From Standard Intervals, Robert Hauser, David Charles, Cynthia Comella, Georg Comes, Michael Hast, Stuart Isaacson
• Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications, Warner Carr, Neal Jain, Wesley Sublett
• Real-World Cost and Utilization Analysis of Botulinum Toxin Agents in Blepharospasm: A National Retrospective Cohort Study, Rashid Kazerooni, Daniel B. Rootman, Robert Goldberg, Liza M. Cohen
• Improvements in upper limb spasticity-related pain in children/adolescents with cerebral palsy after incobotulinumtoxinA injections, Florian Heinen, Michaela Bonfert, Petr Kaňovský, A. Sebastian Schroeder, Henry G. Chambers, Edward Dabrowski, Thorin L. Geister, Angelika Hanschmann, Michael Althaus, Marta Banach, Deborah Gaebler-Spira
• Improvements in lower limb spasticity-related pain in children/adolescents with cerebral palsy after incobotulinumtoxinA injections, Florian Heinen, Michaela Bonfert, Petr Kaňovský, A. Sebastian Schroeder, Henry G. Chambers, Edward Dabrowski, Thorin L. Geister, Angelika Hanschmann, Michael Althaus, Marta Banach, Deborah Gaebler-Spira
• Pain reduction in adult patients with limb spasticity following a single incobotulinumtoxinA injection: an analysis of pooled data from phase 2 and 3 studies, Jörg Wissel, Alexandre Camões-Barbosa, Georg Comes, Michael Althaus, Astrid Scheschonka, David Simpson
• Benefit of multiple incobotulinumtoxinA injections for pain reduction in adult patients with limb spasticity: an analysis of pooled data from phase 2 and 3 studies, Jörg Wissel, Alexandre Camões-Barbosa, Georg Comes, Michael Althaus, Astrid Scheschonka, David Simpson
• Disparities in Access to Spasticity Chemodenervation Specialists in the United States: A National Analysis of Medicare Data, Rashid Kazerooni, Sean Healy, Monica Verduzco-Gutierrez

Presentations will be accessible in the on-site poster hall for the duration of the meeting beginning on Wednesday, July 27. Conference attendees will also have access to the virtual conference hall for six months post-conference.

At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions and other health conditions that severely impact patients’ quality of life. With our patient-centric approach, cutting-edge research and development efforts, highly-scientific medical affairs resources and dedicated commercial teams, we continue the advancement of new and individualized treatment standards, including botulinum toxin. Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve the unmet patient and customer needs.

*Prof. Dr. Florian Heinen is a paid consultant for Merz Pharmaceuticals GmbH.

XEOMIN^® (incobotulinumtoxinA) IMPORTANT CONSUMER SAFETY INFORMATION


Read the Medication Guide before you start receiving XEOMIN^® (Zeo-min) and each time XEOMIN is given to you as there may be new information. The risk information provided here is not comprehensive. To learn more:

• Talk to your health care provider or pharmacist
• Visit www.xeomin.com to obtain the FDA-approved product labeling
• Call 1-844-4MYMERZ (1-844-469-6379)

Uses

XEOMIN is a prescription medicine:

• that is injected into glands that make saliva and is used to treat long-lasting (chronic) drooling (sialorrhea) in adults and in children 2 to 17 years of age.
• that is injected into muscles and used to: treat increased muscle stiffness in the arm because of upper limb spasticity in adults.
  • treat increased muscle stiffness in the arm in children 2 to 17 years of age with upper limb spasticity, excluding spasticity caused by cerebral palsy.
  • treat the abnormal head position and neck pain with cervical dystonia (CD) in adults.
  • treat abnormal spasm of the eyelids (blepharospasm) in adults.

It is not known if XEOMIN is safe and effective in children younger than:

• 2 years of age for the treatment of chronic sialorrhea
• 2 years of age for the treatment of upper limb spasticity
• 18 years of age for the treatment of cervical dystonia or blepharospasm

Warnings

XEOMIN may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of XEOMIN:

• Problems swallowing, speaking or breathing can happen if the muscles that you use to breathe and swallow become weak. Death can happen as a complication if you have severe problems with swallowing or breathing after treatment with XEOMIN.
  • People with certain breathing problems may need to use muscles in their neck to help them breathe and may be at greater risk for serious breathing problems with XEOMIN.
  • Swallowing problems may last for several months, and during that time you may need a feeding tube to receive food and water. If swallowing problems are severe, food or liquids may go into your lungs. People who already have swallowing or breathing problems before receiving XEOMIN have the highest risk of getting these problems.
• Spread of toxin effects. In some cases, the effect of botulinum toxin may affect areas of the body away from the injection site and cause symptoms of a serious condition called botulism. The symptoms of botulism include: loss of strength and muscle weakness all over the body, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing.

These symptoms can happen hours to weeks after you receive an injection of XEOMIN. These problems could make it unsafe for you to drive a car or do other dangerous activities.

Do not take XEOMIN if you: are allergic to XEOMIN or any of the ingredients in XEOMIN (see below for a list of ingredients in XEOMIN), had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (Myobloc^®), onabotulinumtoxinA (Botox^®, Botox^® Cosmetic), or abobotulinumtoxinA (Dysport^®) or have a skin infection at the planned injection site.

Before receiving XEOMIN, tell your doctor about all of your medical conditions, including if you:

• have a disease that affects your muscles and nerves (such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], myasthenia gravis or Lambert-Eaton syndrome)
• have had any side effect from any other botulinum toxin in the past
• have a breathing problem, such as asthma or emphysema
• have a history of swallowing problems or inhaling food or fluid into your lungs (aspiration)
• have drooping eyelids
• have had eye surgery
• have had surgery on your face
• are pregnant or plan to become pregnant. It is not known if XEOMIN can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if XEOMIN passes into breast milk.

Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Talk to your doctor before you take any new medicines after you receive XEOMIN.

Using XEOMIN with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received XEOMIN in the past.
Especially tell your doctor if you:

• have received any other botulinum toxin product in the last four months
• have received injections of botulinum toxin such as rimabotulinumtoxinB (MYOBLOC^®), onabotulinumtoxinA (BOTOX^®, BOTOX^® COSMETIC) and abobotulinumtoxinA (DYSPORT^®) in the past. Be sure your doctor knows exactly which product you received.
• The dose of XEOMIN may be different from other botulinum toxin products that you have received.
• have recently received an antibiotic by injection or inhalation
• take muscle relaxants
• take an allergy or cold medicine
• take a sleep medicine

Ask your doctor if you are not sure if your medicine is one that is listed above.

Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.

Possible Side Effects

XEOMIN can cause serious side effects including:

• Injury to the cornea (the clear front surface of the eye) in people treated for blepharospasm. People who receive XEOMIN to treat spasm of the eyelid may have reduced blinking that can cause a sore on their cornea or other problems of the cornea. Call your healthcare provider or get medical care right away if you have eye pain or irritation after treatment with XEOMIN.
• XEOMIN may cause other serious side effects including allergic reactions. Symptoms of an allergic reaction to XEOMIN may include: itching, rash, redness, swelling, wheezing, trouble breathing or dizziness or feeling faint. Tell your doctor or get medical help right away if you get wheezing or trouble breathing, or if you get dizzy or faint.

The most common side effects of XEOMIN in adults with chronic sialorrhea include:

The most common side effects of XEOMIN in children 2 to 17 years of age with chronic sialorrhea include:

The most common side effects of XEOMIN in adults with upper limb spasticity include:

The most common side effects of XEOMIN in children 2 to 17 years of age with upper limb spasticity include:

The most common side effects of XEOMIN in adults with cervical dystonia include:

The most common side effects of XEOMIN in adults with blepharospasm include:

These are not all the possible side effects of XEOMIN.
Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of XEOMIN
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or doctor for information about XEOMIN that is written for health professionals.

Active Ingredient: botulinum toxin type A

Inactive Ingredients: human albumin and sucrose

Copyright © 2022 Merz Pharmaceuticals, LLC. All rights reserved. MERZ, the MERZ logo, and XEOMIN are registered trademarks of Merz Pharma GmbH & Co. KGaA. Botox, Dysport and Myobloc are registered trademarks of their respective owners.

For more information, please see the XEOMIN full Prescribing Information and Medication Guide at www.xeomin.com.